<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Bioventus Inc — News on 6ix</title>
<link>https://6ix.com/company/bioventus-inc</link>
<description>Latest news and press releases for Bioventus Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 20:15:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/bioventus-inc" rel="self" type="application/rss+xml" />
<item>
<title>Bioventus to Report First Quarter of Fiscal Year 2026 Financial Results on May 6, 2026</title>
<link>https://6ix.com/company/bioventus-inc/news/bioventus-to-report-first-quarter-of-fiscal-year-2026-financial-results-on-may-6-2026</link>
<guid isPermaLink="true">https://6ix.com/company/bioventus-inc/news/bioventus-to-report-first-quarter-of-fiscal-year-2026-financial-results-on-may-6-2026</guid>
<pubDate>Tue, 28 Apr 2026 20:15:00 GMT</pubDate>
<description>DURHAM, N.C., April 28, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2026 before the market opens on Wednesday, May 6, 2026. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1</description>
</item>
<item>
<title>Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/bioventus-inc/news/bioventus-announces-fourth-quarter-and-full-year-2025-financial-results-7</link>
<guid isPermaLink="true">https://6ix.com/company/bioventus-inc/news/bioventus-announces-fourth-quarter-and-full-year-2025-financial-results-7</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>Q4 reported revenue of $157.9 million increased 2.8% and organic* revenue increased 10.0%Fourth quarter GAAP earnings of $0.21 per diluted share compared to</description>
</item>
<item>
<title>Bioventus to Report Fourth Quarter of Fiscal Year 2025 Financial Results on March 5, 2026</title>
<link>https://6ix.com/company/bioventus-inc/news/bioventus-to-report-fourth-quarter-of-fiscal-year-2025-financial-results-on-march-5-2026</link>
<guid isPermaLink="true">https://6ix.com/company/bioventus-inc/news/bioventus-to-report-fourth-quarter-of-fiscal-year-2025-financial-results-on-march-5-2026</guid>
<pubDate>Tue, 24 Feb 2026 21:15:00 GMT</pubDate>
<description>DURHAM, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2025 before the market opens on Thursday, March 5, 2026. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial</description>
</item>
<item>
<title>Bioventus to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/bioventus-inc/news/bioventus-present-44th-annual-j-123000434</link>
<guid isPermaLink="true">https://6ix.com/company/bioventus-inc/news/bioventus-present-44th-annual-j-123000434</guid>
<pubDate>Tue, 06 Jan 2026 12:30:00 GMT</pubDate>
<description>DURHAM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob...</description>
</item>
<item>
<title>Bioventus to Present at the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/bioventus-inc/news/bioventus-present-piper-sandler-37th-211500845</link>
<guid isPermaLink="true">https://6ix.com/company/bioventus-inc/news/bioventus-present-piper-sandler-37th-211500845</guid>
<pubDate>Tue, 25 Nov 2025 21:15:00 GMT</pubDate>
<description>DURHAM, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Bioventus President and Chief Executive Officer, will present at the Piper Sandler Healthcare Conference on Wednesday, December 3, 2025, at 10:10 a.m. ET. A live webcast of the presentation, followed by a question-and-answer session will be available on the “Investors” section of the Company’s website at www.bioventus.com and will be</description>
</item>
<item>
<title>Bioventus Reports Third Quarter Financial Results</title>
<link>https://6ix.com/company/bioventus-inc/news/bioventus-reports-third-quarter-financial-123000766</link>
<guid isPermaLink="true">https://6ix.com/company/bioventus-inc/news/bioventus-reports-third-quarter-financial-123000766</guid>
<pubDate>Tue, 04 Nov 2025 12:30:00 GMT</pubDate>
<description>Q3 reported revenue of $138.7 million was comparable to last year and organic* revenue advanced 8%Third quarter GAAP earnings of $0.05 per diluted share increased compared to the prior-year period loss of $0.08 per diluted shareNon-GAAP earnings* of $0.15 per diluted share increased 200%Cash from operations of $30.1 million increased 192%Company reaffirms revenue, Adjusted EBITDA* and Non-GAAP EPS* guidance for full year 2025 DURHAM, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq</description>
</item>
<item>
<title>Bioventus to Report Third Quarter of Fiscal Year 2025 Financial Results on November 4, 2025</title>
<link>https://6ix.com/company/bioventus-inc/news/bioventus-report-third-quarter-fiscal-110000252</link>
<guid isPermaLink="true">https://6ix.com/company/bioventus-inc/news/bioventus-report-third-quarter-fiscal-110000252</guid>
<pubDate>Tue, 28 Oct 2025 11:00:00 GMT</pubDate>
<description>DURHAM, N.C., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2025 before the market opens on Tuesday, November 4, 2025. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial</description>
</item>
<item>
<title>Bioventus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference</title>
<link>https://6ix.com/company/bioventus-inc/news/bioventus-present-morgan-stanley-23rd-113000363</link>
<guid isPermaLink="true">https://6ix.com/company/bioventus-inc/news/bioventus-present-morgan-stanley-23rd-113000363</guid>
<pubDate>Wed, 03 Sep 2025 11:30:00 GMT</pubDate>
<description>DURHAM, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, Bioventus Senior Vice-President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Wednesday, September 10, 2025, at 1:05 p.m. ET. A live webcast of the presentation will be available on the “Investors” section of the Company’s website at www.bioventus.com and will</description>
</item>
<item>
<title>Bioventus to Present at the Canaccord Genuity 45th Annual Global Growth Conference</title>
<link>https://6ix.com/company/bioventus-inc/news/bioventus-present-canaccord-genuity-45th-201500606</link>
<guid isPermaLink="true">https://6ix.com/company/bioventus-inc/news/bioventus-present-canaccord-genuity-45th-201500606</guid>
<pubDate>Thu, 07 Aug 2025 20:15:00 GMT</pubDate>
<description>DURHAM, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Bioventus President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity Global Growth Conference on Tuesday, August 12, 2025, at 2:00 p.m. ET. A live webcast of the presentation, followed by a question-and-answer session will be available on the “Investors” section of the Company’s website at www</description>
</item>
<item>
<title>Bioventus Reports Second Quarter Financial Results</title>
<link>https://6ix.com/company/bioventus-inc/news/bioventus-reports-second-quarter-financial-110000463</link>
<guid isPermaLink="true">https://6ix.com/company/bioventus-inc/news/bioventus-reports-second-quarter-financial-110000463</guid>
<pubDate>Wed, 06 Aug 2025 11:00:00 GMT</pubDate>
<description>Q2 reported revenue of $147.7 million declined 2.4%; Organic* revenue advanced 6.2%Second quarter diluted earnings per share was $0.11 compared to a diluted loss per share of $0.40 in the prior-year periodNon-GAAP earnings* of $0.21 per share increased 31%Cash from operations of $25.9 million increased 71%Company reiterated revenue, Adjusted EBITDA* and Non-GAAP EPS* guidance for full year 2025 DURHAM, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Comp</description>
</item>
<item>
<title>Bioventus Enters into a New $400 Million Senior Secured Credit Agreement Lowering Interest Expense and Providing Increased Liquidity</title>
<link>https://6ix.com/company/bioventus-inc/news/bioventus-enters-400-million-senior-120000815</link>
<guid isPermaLink="true">https://6ix.com/company/bioventus-inc/news/bioventus-enters-400-million-senior-120000815</guid>
<pubDate>Mon, 04 Aug 2025 12:00:00 GMT</pubDate>
<description>DURHAM, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it has entered into a $400 million Senior Secured Credit Agreement (the “Credit Agreement”) consisting of a $300 million term loan facility and a $100 million revolving credit facility on July 31, 2025. The new Credit Agreement will mature on July 31, 2030. Among the many enhancements, the new Credit Agreement provide</description>
</item>
<item>
<title>Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products</title>
<link>https://6ix.com/company/bioventus-inc/news/bioventus-receives-fda-510-k-113000698</link>
<guid isPermaLink="true">https://6ix.com/company/bioventus-inc/news/bioventus-receives-fda-510-k-113000698</guid>
<pubDate>Wed, 30 Jul 2025 11:30:00 GMT</pubDate>
<description>DURHAM, N.C., July 30, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, announced today a significant milestone with the U.S. Food and Drug Administration (FDA) 510(k) clearances for both TalisMann™ and StimTrial™, expanding the Company’s innovative portfolio of Peripheral Nerve Stimulation (PNS) solutions for chronic pain management. These two clearances mark an important step forward for Bioventus and represent a substantial growth oppor</description>
</item>
<item>
<title>Bioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025</title>
<link>https://6ix.com/company/bioventus-inc/news/bioventus-report-second-quarter-fiscal-201500098</link>
<guid isPermaLink="true">https://6ix.com/company/bioventus-inc/news/bioventus-report-second-quarter-fiscal-201500098</guid>
<pubDate>Tue, 29 Jul 2025 20:15:00 GMT</pubDate>
<description>DURHAM, N.C., July 29, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2025 before the market opens on Wednesday, August 6, 2025. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dia</description>
</item>
<item>
<title>Bioventus Reports First Quarter Financial Results</title>
<link>https://6ix.com/company/bioventus-inc/news/bioventus-reports-first-quarter-financial-113000536</link>
<guid isPermaLink="true">https://6ix.com/company/bioventus-inc/news/bioventus-reports-first-quarter-financial-113000536</guid>
<pubDate>Tue, 06 May 2025 11:30:00 GMT</pubDate>
<description>Q1 reported revenue of $123.9 million declined 4.3%; Organic* revenue advanced 5.0%First quarter net loss was $0.04 per share compared to a loss of $0.08 in the prior-year periodNon-GAAP earnings* of $0.08 per share increased 33%Company reiterated revenue, Adjusted EBITDA* and Non-GAAP EPS* guidance for full year 2025 DURHAM, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financ</description>
</item>
<item>
<title>Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025</title>
<link>https://6ix.com/company/bioventus-inc/news/bioventus-report-first-quarter-fiscal-120000447</link>
<guid isPermaLink="true">https://6ix.com/company/bioventus-inc/news/bioventus-report-first-quarter-fiscal-120000447</guid>
<pubDate>Mon, 28 Apr 2025 12:00:00 GMT</pubDate>
<description>DURHAM, N.C., April 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2025 before the market opens on Tuesday, May 6, 2025. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-8</description>
</item>
<item>
<title>Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results</title>
<link>https://6ix.com/company/bioventus-inc/news/bioventus-announces-fourth-quarter-full-113000810</link>
<guid isPermaLink="true">https://6ix.com/company/bioventus-inc/news/bioventus-announces-fourth-quarter-full-113000810</guid>
<pubDate>Tue, 11 Mar 2025 11:30:00 GMT</pubDate>
<description>Accelerated fourth quarter sales growth to 13.5%Fourth quarter gross margin expanded 310 bps and adjusted gross margin* expanded 230 bpsFourth quarter cash from operations of $19.3 million increased 86.3%Provides full-year 2025 financial guidance reflecting continued above market revenue growth and continued operating margin expansion DURHAM, N.C., March 11, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, to</description>
</item>
<item>
<title>Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025</title>
<link>https://6ix.com/company/bioventus-inc/news/bioventus-report-fourth-quarter-fiscal-123000091</link>
<guid isPermaLink="true">https://6ix.com/company/bioventus-inc/news/bioventus-report-fourth-quarter-fiscal-123000091</guid>
<pubDate>Fri, 28 Feb 2025 12:30:00 GMT</pubDate>
<description>DURHAM, N.C., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2024 before the market opens on Tuesday, March 11, 2025. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial</description>
</item>
<item>
<title>Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners</title>
<link>https://6ix.com/company/bioventus-inc/news/bioventus-completes-divestiture-of-its-advanced-rehabilitation-business-to-accelmed-partners</link>
<guid isPermaLink="true">https://6ix.com/company/bioventus-inc/news/bioventus-completes-divestiture-of-its-advanced-rehabilitation-business-to-accelmed-partners</guid>
<pubDate>Thu, 02 Jan 2025 05:00:00 GMT</pubDate>
<description>DURHAM, N.C., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active</description>
</item>
<item>
<title>Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024</title>
<link>https://6ix.com/company/bioventus-inc/news/bioventus-to-report-third-quarter-of-fiscal-year-2024-financial-results-on-november-5-2024</link>
<guid isPermaLink="true">https://6ix.com/company/bioventus-inc/news/bioventus-to-report-third-quarter-of-fiscal-year-2024-financial-results-on-november-5-2024</guid>
<pubDate>Tue, 29 Oct 2024 04:00:00 GMT</pubDate>
<description>DURHAM, N.C., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active</description>
</item>
<item>
<title>Bioventus Announces Divestiture of its Advanced Rehabilitation Business to Accelmed Partners</title>
<link>https://6ix.com/company/bioventus-inc/news/bioventus-announces-divestiture-of-its-advanced-rehabilitation-business-to-accelmed-partners</link>
<guid isPermaLink="true">https://6ix.com/company/bioventus-inc/news/bioventus-announces-divestiture-of-its-advanced-rehabilitation-business-to-accelmed-partners</guid>
<pubDate>Tue, 01 Oct 2024 04:00:00 GMT</pubDate>
<description>DURHAM, N.C., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active</description>
</item>
</channel>
</rss>